The Precision Peptide Company Inc. PNGAF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.90K | 12.00K | 31.00K | 31.60K | 4.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.90K | 12.00K | 31.00K | 31.60K | 4.30K |
| Cost of Revenue | 20.10K | 12.20K | 5.40K | 18.60K | 1.40K |
| Gross Profit | 25.80K | -200.00 | 25.60K | 12.90K | 2.90K |
| SG&A Expenses | 1.19M | 342.50K | 1.03M | 771.10K | 485.00K |
| Depreciation & Amortization | -- | -- | -- | 33.30K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.20M | 361.60K | 1.07M | 842.20K | 486.50K |
| Operating Income | -1.16M | -349.70K | -1.04M | -810.70K | -482.10K |
| Income Before Tax | -1.28M | -377.50K | -1.01M | -2.45M | -477.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.28M | -377.50K | -1.01M | -2.45M | -477.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.28M | -377.50K | -1.01M | -2.45M | -477.00K |
| EBIT | -1.16M | -349.70K | -1.04M | -810.70K | -482.10K |
| EBITDA | -1.14M | -333.10K | -1.02M | -777.30K | -471.30K |
| EPS Basic | -0.03 | -0.01 | -0.03 | -0.05 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.03 | -0.01 | -0.03 | -0.05 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 48.06M | 42.53M | 40.48M | 45.44M | 28.25M |
| Average Diluted Shares Outstanding | 48.06M | 42.53M | 40.48M | 45.44M | 28.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |